<p>Bausch Health Companies Inc. (TSE:BHC - 免费报告) - Zacks Research 的股票分析师在 3 月 11 日星期三发布的报告中上调了 Bausch Health Companies 2026 年第二季度每股收益（EPS）预期。Zacks Research 分析师团队现在预测该公司本季度每股收益为 1.28 美元，高于之前的 1.27 美元预期。Bausch Health Companies 当前全年的共识预期每股收益为 5.55 美元。Zacks Research 还发布了 Bausch Health Companies 2027 年第三季度每股收益预期为 1.52 美元，以及 2028 财年的每股收益预期为 4.56 美元。</p>
<p>Bausch Health Companies (TSE:BHC - 获取免费报告) 最近在 2 月 18 日星期三公布了季度财报。该公司报告本季度每股收益为 C($0.41)。该季度的收入为 66.2 亿加元。Bausch Health Companies 的净利润率为 1.82%，股本回报率为负 20.27%。</p>
<p>其他几位股票分析师最近也对 BHC 发表了评论。Raymond James Financial 在 12 月 15 日星期一的研究报告中将 Bausch Health Companies 的评级上调至 “持有”。巴克莱在 12 月 8 日星期一的报告中也将 Bausch Health Companies 的评级上调至 “持有”。根据 MarketBeat.com 的数据，两位股票研究分析师对该股票给予了 “持有” 评级，该股票的平均评级为 “持有”。</p>
<p><strong>查看我们对 Bausch Health Companies 的最新股票分析</strong></p>
<h2>Bausch Health Companies 股价下跌 6.5%</h2>
<p>BHC 股票在星期五开盘价为 6.89 加元。该公司的 50 日移动平均价格为 8.56 加元，200 日移动平均价格为 9.07 加元。该公司的速动比率为 0.58，流动比率为 1.47，负债权益比率为 -3,835.02。该公司的市值为 25.5 亿加元，市盈率为 16.40，市盈增长比率为 0.21，贝塔值为 0.60。Bausch Health Companies 的 12 个月低点为 5.91 加元，12 个月高点为 11.97 加元。</p>
<h2>Bausch Health Companies 新闻汇总</h2>
<p>以下是本周影响 Bausch Health Companies 的主要新闻：</p>
<ul>
<li>积极情绪：Zacks 上调了近期季度预期：2027 年第三季度每股收益从 1.42 美元上调至 1.52 美元，2026 年第二季度每股收益从 1.27 美元上调至 1.28 美元——对近期增长预期的温和上行。文章标题</li>
<li>积极情绪：Zacks 还上调了其他几个季度的预测：2027 年第一季度（1.09 → 1.11）和 2026 年第四季度（1.46 → 1.49），如果销售/利润率跟随，这可能会支持即将公布的季度业绩。文章标题</li>
<li>中性情绪：Zacks 发布了 2028 财年每股收益预期为 4.56 美元，并重申当前全年的共识/预期接近 5.55 美元——这些长期数据提供了背景，但距离近期市场反应较远。文章标题</li>
<li>消极情绪：几项显著的下调：2027 年第四季度大幅下调（从 1.47 美元降至 1.32 美元）和 2027 年第二季度下调（1.32 → 1.20）——这些减少表明 Zacks 预计 2027 财年后期的增长放缓或利润压力。文章标题</li>
<li>消极情绪：Zacks 下调了其他多个预测，包括 2026 年第三季度（1.50 → 1.44）、2026 年第一季度（1.13 → 1.10）、2026 财年（5.37 → 5.32）和 2027 财年（5.30 → 5.15），表明预期收益低于之前的估计，并对估值施加下行压力。文章标题</li>
</ul>
<h2>Bausch Health Companies 公司简介</h2>
<p>(获取免费报告)</p>
<p>Bausch Health Companies Inc 是一家全球公司，开发、制造和销售一系列制药、医疗器械和非处方产品，主要涉及眼健康、胃肠病学和皮肤病学等治疗领域。我们正在履行我们的承诺，建立一家致力于推动全球健康的创新公司。我们大约 22000 名员工团结在改善人们生活的使命下，我们在大约 100 个国家直接或间接地制造和销售医疗保健产品。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Bausch Health Companies</li>
<li>华尔街害怕的黄金图表……</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>白银支付 20% 股息。此外 68% 股份收益</li>
<li>1500 家银行刚刚把你的银行账户交给了美联储</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9QkhD?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9QkhD"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Bausch Health Companies 吗？</h2>
<p>在你考虑投资 Bausch Health Companies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bausch Health Companies 并不在名单上。</p>
<p>虽然 Bausch Health Companies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

<p>Zacks Research 将 Bausch Health Companies (TSE:BHC) 2026 年第二季度每股收益（EPS）预估从 1.27 美元上调至 1.28 美元，全年预估为每股 5.55 美元。该公司还预测 2027 年第三季度的收益为 1.52 美元，2028 财年的收益为 4.56 美元。尽管最近季度每股亏损为 0.41 加元，分析师仍对该股票维持 “持有” 评级，该股最近下跌了 6.5%。该公司的市值为 25.5 亿加元，市盈率为 16.40，过去 12 个月的交易区间在 5.91 加元至 11.97 加元之间</p>

<p>Bausch Health Companies Inc. (TSE:BHC - Free Report) - Stock analysts at Zacks Research upped their Q2 2026 EPS estimates for shares of Bausch Health Companies in a report issued on Wednesday, March 11th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $1.28 for the quarter, up from their prior estimate of $1.27. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q3 2027 earnings at $1.52 EPS and FY2028 earnings at $4.56 EPS.</p>
<div class="lb-trans"><p>Bausch Health Companies Inc. (TSE:BHC - 免费报告) - Zacks Research 的股票分析师在 3 月 11 日星期三发布的报告中上调了 Bausch Health Companies 2026 年第二季度每股收益（EPS）预期。Zacks Research 分析师团队现在预测该公司本季度每股收益为 1.28 美元，高于之前的 1.27 美元预期。Bausch Health Companies 当前全年的共识预期每股收益为 5.55 美元。Zacks Research 还发布了 Bausch Health Companies 2027 年第三季度每股收益预期为 1.52 美元，以及 2028 财年的每股收益预期为 4.56 美元。</p>
</div><p>Bausch Health Companies (TSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 18th. The company reported C($0.41) EPS for the quarter. The company had revenue of C$6.62 billion during the quarter. Bausch Health Companies had a net margin of 1.82% and a negative return on equity of 20.27%.</p>
<div class="lb-trans"><p>Bausch Health Companies (TSE:BHC - 获取免费报告) 最近在 2 月 18 日星期三公布了季度财报。该公司报告本季度每股收益为 C($0.41)。该季度的收入为 66.2 亿加元。Bausch Health Companies 的净利润率为 1.82%，股本回报率为负 20.27%。</p>
</div><p>Several other equities analysts also recently commented on BHC. Raymond James Financial raised Bausch Health Companies to a &#34;hold&#34; rating in a research report on Monday, December 15th. Barclays raised Bausch Health Companies to a &#34;hold&#34; rating in a report on Monday, December 8th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock has an average rating of &#34;Hold&#34;.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对 BHC 发表了评论。Raymond James Financial 在 12 月 15 日星期一的研究报告中将 Bausch Health Companies 的评级上调至 “持有”。巴克莱在 12 月 8 日星期一的报告中也将 Bausch Health Companies 的评级上调至 “持有”。根据 MarketBeat.com 的数据，两位股票研究分析师对该股票给予了 “持有” 评级，该股票的平均评级为 “持有”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Bausch Health Companies</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Bausch Health Companies 的最新股票分析</strong></p>
</div><h2>Bausch Health Companies Trading Down 6.5%</h2>
<div class="lb-trans"><h2>Bausch Health Companies 股价下跌 6.5%</h2>
</div><p>Shares of BHC stock opened at C$6.89 on Friday. The firm has a 50 day moving average price of C$8.56 and a two-hundred day moving average price of C$9.07. The company has a quick ratio of 0.58, a current ratio of 1.47 and a debt-to-equity ratio of -3,835.02. The company has a market capitalization of C$2.55 billion, a PE ratio of 16.40, a price-to-earnings-growth ratio of 0.21 and a beta of 0.60. Bausch Health Companies has a 12-month low of C$5.91 and a 12-month high of C$11.97.</p>
<div class="lb-trans"><p>BHC 股票在星期五开盘价为 6.89 加元。该公司的 50 日移动平均价格为 8.56 加元，200 日移动平均价格为 9.07 加元。该公司的速动比率为 0.58，流动比率为 1.47，负债权益比率为 -3,835.02。该公司的市值为 25.5 亿加元，市盈率为 16.40，市盈增长比率为 0.21，贝塔值为 0.60。Bausch Health Companies 的 12 个月低点为 5.91 加元，12 个月高点为 11.97 加元。</p>
</div><h2>Bausch Health Companies News Roundup</h2>
<div class="lb-trans"><h2>Bausch Health Companies 新闻汇总</h2>
</div><p>Here are the key news stories impacting Bausch Health Companies this week:</p>
<div class="lb-trans"><p>以下是本周影响 Bausch Health Companies 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Zacks raised near‑term quarter estimates: Q3 2027 EPS was lifted from $1.42 to $1.52 and Q2 2026 EPS was nudged from $1.27 to $1.28 — modest upside to near‑term growth expectations. Article Title</li>
<li>Positive Sentiment: Zacks also bumped a few other quarterly forecasts: Q1 2027 (1.09 → 1.11) and Q4 2026 (1.46 → 1.49), which could support upcoming quarterly results if sales/margins follow. Article Title</li>
<li>Neutral Sentiment: Zacks published a FY2028 EPS outlook of $4.56 and reiterates a consensus/current full‑year estimate near $5.55 — these longer‑range figures provide context but are farther from near‑term market reaction. Article Title</li>
<li>Negative Sentiment: Several notable downward revisions: Q4 2027 cut substantially (from $1.47 to $1.32) and Q2 2027 cut (1.32 → 1.20) — these reductions suggest Zacks expects slower growth or margin pressure later in FY2027. Article Title</li>
<li>Negative Sentiment: Zacks trimmed multiple other forecasts including Q3 2026 (1.50 → 1.44), Q1 2026 (1.13 → 1.10), FY2026 (5.37 → 5.32) and FY2027 (5.30 → 5.15), signaling lower expected earnings vs prior estimates and applying downward pressure to valuation. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Zacks 上调了近期季度预期：2027 年第三季度每股收益从 1.42 美元上调至 1.52 美元，2026 年第二季度每股收益从 1.27 美元上调至 1.28 美元——对近期增长预期的温和上行。文章标题</li>
<li>积极情绪：Zacks 还上调了其他几个季度的预测：2027 年第一季度（1.09 → 1.11）和 2026 年第四季度（1.46 → 1.49），如果销售/利润率跟随，这可能会支持即将公布的季度业绩。文章标题</li>
<li>中性情绪：Zacks 发布了 2028 财年每股收益预期为 4.56 美元，并重申当前全年的共识/预期接近 5.55 美元——这些长期数据提供了背景，但距离近期市场反应较远。文章标题</li>
<li>消极情绪：几项显著的下调：2027 年第四季度大幅下调（从 1.47 美元降至 1.32 美元）和 2027 年第二季度下调（1.32 → 1.20）——这些减少表明 Zacks 预计 2027 财年后期的增长放缓或利润压力。文章标题</li>
<li>消极情绪：Zacks 下调了其他多个预测，包括 2026 年第三季度（1.50 → 1.44）、2026 年第一季度（1.13 → 1.10）、2026 财年（5.37 → 5.32）和 2027 财年（5.30 → 5.15），表明预期收益低于之前的估计，并对估值施加下行压力。文章标题</li>
</ul>
</div><h2>Bausch Health Companies Company Profile</h2>
<div class="lb-trans"><h2>Bausch Health Companies 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.</p>
<div class="lb-trans"><p>Bausch Health Companies Inc 是一家全球公司，开发、制造和销售一系列制药、医疗器械和非处方产品，主要涉及眼健康、胃肠病学和皮肤病学等治疗领域。我们正在履行我们的承诺，建立一家致力于推动全球健康的创新公司。我们大约 22000 名员工团结在改善人们生活的使命下，我们在大约 100 个国家直接或间接地制造和销售医疗保健产品。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Bausch Health Companies</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Unlocked: Elon Musk’s Next Big IPO</li>
<li>Silver paying 20% dividend. Plus 68% share gains</li>
<li>1,500 Banks Just Handed the Fed Your Bank Account</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Bausch Health Companies</li>
<li>华尔街害怕的黄金图表……</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>解锁：埃隆·马斯克的下一个大 IPO</li>
<li>白银支付 20% 股息。此外 68% 股份收益</li>
<li>1500 家银行刚刚把你的银行账户交给了美联储</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PVRTRSZTeW1ib2w9QkhD" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=TSE&amp;Symbol=BHC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bausch Health Companies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bausch Health Companies 吗？</h2>
</div><p>Before you consider Bausch Health Companies, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Bausch Health Companies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bausch Health Companies 并不在名单上。</p>
</div><p>While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bausch Health Companies 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Zacks 研究对 TSE:BHC 的收益发布了乐观的预期